JERUSALEM--(BUSINESS WIRE)--May 18, 2006--BioLineRx Ltd., Israel’s leading drug development company, will present a poster regarding BL-1020, its lead compound currently being studied as a treatment for schizophrenia, at two leading scientific psychiatric meetings: the American Psychiatric Association Annual Meeting, May 20-25, Toronto; and the Society of Biological Psychiatry Annual Scientific Program and Convention, May 18-20, Toronto.
